Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise

Searching For A Functional Cure

The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.

ILC Congress 2022 London — Numerous new studies aiming for a functional cure in hepatitis B are being presented at the International Liver Congress in London. • Source: EASL

Shares in UK-based Vaccitech climbed by more than 40% after it reported encouraging early results from its ChAdOx1 vaccine platform used in a hepatitis B therapy, which looked strongest when combined with Bristol Myers Squibb’s immuno-oncology product Opdivo.

The news lifted the NASDAQ-listed company’s share price to $5.82 on 23 June, suggesting renewed belief in its next vaccine/immunotherapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

31 Jul 2025

• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

31 Jul 2025

• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

31 Jul 2025

• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

31 Jul 2025

• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

31 Jul 2025

• By Mandy Jackson

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.